{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T22:15:35Z","timestamp":1715811335299},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Under\u2010reporting of adverse drug reactions to regulatory authorities is common, and there is concern about falling numbers of general practitioner reports.<\/jats:p><jats:p>\u2022\u2003Although previous work has suggested high prescribers are less interested in pharmacovigilance, a recent examination of reporting to the Yellow Card scheme has suggested ADR reporting is correlated with high prescribing rates.<\/jats:p><jats:p>\u2022\u2003This study aimed to examine influences on the reporting of ADRs to the Yellow Card scheme in primary care.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003High prescribing rates within primary care are correlated with low ADR reporting rates.<\/jats:p><jats:p>\u2022\u2003Several Primary Care Trust characteristics related to general practitioners, such as increased proportions of single\u2010handed general practitioners and larger list sizes, are associated with low ADR reporting rates.<\/jats:p><jats:p><jats:bold>AIM(S)<\/jats:bold> To examine Primary Care Trust (PCT) demographics influencing general practitioner (GP) involvement in pharmacovigilance.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> PCT adverse drug reaction (ADR) reports to the Yellow Card scheme between April 2004 and March 2006 were obtained for the UK West Midlands region. Reports were analysed by all drugs, and most commonly reported drugs (\u2018top drugs\u2019). PCT data, adjusted for population size, were aggregated. Prescribing statistics and other characteristics were obtained for each PCT, and associations between these characteristics and ADR reporting rates were examined.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> During 2004\u201306, 1175 reports were received from PCTs. Two hundred and eighty (24%) of these reports were for 14 \u2018top drugs\u2019. The mean rate of reporting for PCTs was 213 reports per million population. A total of 153 million items were prescribed during 2004\u201306, of which 33% were \u2018top drugs\u2019. Reports for all drugs and \u2018top drugs\u2019 were inversely correlated with the number of prescriptions issued per thousand population (<jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub>=\u22120.413, 95% CI \u22120.673, \u22120.062, <jats:italic>P<\/jats:italic> &lt; 0.05, and <jats:italic>r<\/jats:italic>=\u22120.420, 95% CI \u22120.678, \u22120.071, <jats:italic>P<\/jats:italic> &lt; 0.05, respectively). Reporting was significantly negatively correlated with the percentages of male GPs within a PCT, GPs over 55 years of age, single\u2010handed GPs within a PCT, the average list size of a GP within a PCT, the overall deprivation scores and average QOF total points. ADR reports did not correlate significantly with the proportion of the population over 65 years old.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> Some PCT characteristics appear to be associated with low levels of ADR reporting. The association of low prescribing areas with high ADR reporting rates replicates previous findings.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03637.x","type":"journal-article","created":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T14:21:34Z","timestamp":1265034094000},"page":"529-534","source":"Crossref","is-referenced-by-count":6,"title":["Correlates of spontaneous reporting of adverse drug reactions within primary care: the paradox of low prescribers who are high reporters"],"prefix":"10.1111","volume":"69","author":[{"given":"Anthony R.","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin E.","family":"Ferner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1248"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629020-00008"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_6_5_2","unstructured":"House of Commons Committee of Public Accounts.Safety Quality Efficacy: Regulating Medicines in the UK. London:The Stationery Office 2003."},{"key":"e_1_2_6_6_2","volume-title":"Safety, Quality, Efficacy: Regulating Medicines in the UK","year":"2003"},{"key":"e_1_2_6_7_2","volume-title":"Report of an Independent Review of Access to the Yellow Card Scheme","author":"Metters J","year":"2004"},{"key":"e_1_2_6_8_2","volume-title":"The Influence of the Pharmaceutical Industry","author":"House of Commons Health Committee","year":"2005"},{"key":"e_1_2_6_9_2","volume-title":"Reporting adverse drug reactions: a guide for healthcare professionals","author":"BMA Board of Science","year":"2006"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730040-00008"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91763-C"},{"key":"e_1_2_6_12_2","first-page":"53","volume-title":"New drugs in general practice: prescribing patterns and external influences","author":"Florentinus SR","year":"2006"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1667"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0037-7856(75)90027-X"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/16.4.407"},{"key":"e_1_2_6_16_2","first-page":"9","article-title":"Time for carrots and sticks on ADR reporting?","volume":"17","author":"Dean T","year":"2006","journal-title":"Prescriber"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03637.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03637.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:16:01Z","timestamp":1697408161000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03637.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,12]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03637.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03637.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,12]]}}}